CEO Comments

Read more:

Categories

Archive per year

CEO Comment Q3 2023

WELL-POSITIONED FOR THE NEXT PHASE Our focus during the third quarter has mainly been on production and financing. We are now producing on a large scale in our production line, while having secured financing to intensify our investments in preparative chromatography and deliver on the order book we are starting to build. During the third quarter, we received several orders for the evaluation of NLAB Saga®, our silica for preparative chromatography, including one order from

Read more »

CEO Comment in Connection with the Preferential Rights Issue 2022

In 2022, Nanologica has taken important steps forward in the chromatography business area. We have scaled up the production of our commercial silica for preparative chromatography, NLAB Saga®, to tonal scale, and we have sold the first products in preparative chromatography, as well as taken orders for NLAB Saga® for production-scale evaluation from one of the world’s largest insulin manufacturers. The fact that we now have products from our large-scale production means that we can

Read more »

CEO Comment Q2 2022

ORDER FROM INSULIN MANUFACTURERS LAYS FOUNDATION FOR CHARGING FORWARD During the quarter, we launched our product line NLAB Saga® for preparative chromatography, after finalizing large volumes of the first products at the large-scale production facility. NLAB Saga® has initially been very well received by customers, which was shown by an order from one of the world’s largest insulin manufacturers in August, for evaluation of the product at production scale. If the products meet the customer’s

Read more »

CEO Comment Q1 2022

A NEW CHAPTER BEGINS  On March 29, 2022, a new chapter in Nanologica’s history began – as listed on a regulated market. By listing the share on Nasdaq Stockholm Main Market, we get an increased exposure and a better opportunity to attract institutional and international owners.  At the same time, we are now launching our products for preparative chromatography. The big event of the quarter was the change of lists to Nasdaq Stockholm Main Market,

Read more »

CEO Comment Q4 2021

AN EXCITING TIME AHEAD During the year, major changes have been made in the company’s two business areas; in Chromatography, Nanologica now focuses mainly on preparative chromatography, and in Drug Development the strategy has been refined to focus on inhaled drugs and respiratory diseases. This has been done to create the best possible growth conditions and value development going forward, for each business area as well as for the company as a whole. In line

Read more »

CEO comment third quarter 2021

FOCUS ON PRODUCTION! Net sales for the quarter increased marginally to TSEK 2,119, most of which again is derived from our partner project with Vicore Pharma. The quarter’s increased operating loss compared to the previous year is according to plan and is mainly due to the expansion phase in which the company is currently in. To take the next step in our growth, we are now fully focused on completing large-scale production capacity, which is

Read more »